Aclaris Therapeutics will present at the H.C. Wainwright Inflammation & Immunology Conference on June 30, 2025.
Quiver AI Summary
Aclaris Therapeutics, Inc. announced that it will present at the H.C. Wainwright Inflammation & Immunology Virtual Conference on June 30, 2025, at 11:30 AM EDT. The presentation will be available via a live and archived webcast on their website for at least 30 days. Aclaris is a clinical-stage biopharmaceutical company focused on developing innovative treatments for immuno-inflammatory diseases, aiming to address unmet patient needs with its diverse product pipeline and strong R&D capabilities. For more information, interested parties are directed to visit their website and follow them on social media platforms.
Potential Positives
- Aclaris Therapeutics will present at the H.C. Wainwright Inflammation & Immunology Virtual Conference, highlighting its commitment to addressing immuno-inflammatory diseases.
- The company’s participation in a prominent industry conference may enhance its visibility among investors and industry stakeholders.
- The availability of a live and archived webcast allows wider access to the presentation, potentially reaching a larger audience interested in Aclaris' developments.
- Aclaris emphasizes its development of novel product candidates for patients with unmet needs, showcasing its focus on innovation in healthcare.
Potential Negatives
- None
FAQ
When is Aclaris Therapeutics' corporate presentation?
Aclaris Therapeutics will present on June 30, 2025, at 11:30 AM EDT.
How can I access the Aclaris presentation?
The presentation will be available via a live and archived webcast on the Aclaris website.
Where can I find more information about Aclaris Therapeutics?
More information is available at Aclaris' website, www.aclaristx.com.
What is Aclaris Therapeutics focused on?
Aclaris is focused on developing novel product candidates for immuno-inflammatory diseases.
How long will the webcast be available?
The webcast will be available on the Aclaris website for at least 30 days after the presentation.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ACRS Hedge Fund Activity
We have seen 60 institutional investors add shares of $ACRS stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC removed 2,799,759 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $4,283,631
- SAMSARA BIOCAPITAL, LLC removed 2,385,060 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $3,649,141
- MILLENNIUM MANAGEMENT LLC added 2,175,101 shares (+111.0%) to their portfolio in Q1 2025, for an estimated $3,327,904
- TRIUM CAPITAL LLP removed 1,912,990 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $4,744,215
- DECHENG CAPITAL LLC added 1,775,069 shares (+78.3%) to their portfolio in Q1 2025, for an estimated $2,715,855
- MORGAN STANLEY added 1,343,800 shares (+125.4%) to their portfolio in Q1 2025, for an estimated $2,056,014
- SUSQUEHANNA INTERNATIONAL GROUP, LLP added 1,302,694 shares (+1648.0%) to their portfolio in Q1 2025, for an estimated $1,993,121
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$ACRS Analyst Ratings
Wall Street analysts have issued reports on $ACRS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Wedbush issued a "Outperform" rating on 05/28/2025
- H.C. Wainwright issued a "Buy" rating on 05/14/2025
- Scotiabank issued a "Outperform" rating on 03/07/2025
To track analyst ratings and price targets for $ACRS, check out Quiver Quantitative's $ACRS forecast page.
Full Release
WAYNE, Pa., June 26, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide a corporate presentation during the H.C. Wainwright Inflammation & Immunology Virtual Conference. The presentation will take place on Monday, June 30, 2025 at 11:30 AM EDT.
A live and archived webcast of the presentation will be accessible on the Events page of https://www.aclaristx.com/ . The webcast will be available on the Aclaris website for at least 30 days.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .
Aclaris Therapeutics Contact:
Will Roberts
Senior Vice President
Corporate Communications and Investor Relations
(484) 329-2125
[email protected]
